Krakow, Poland, November 30, 2017 / B3C newswire / -- The Supervisory Board of Selvita S.A. (WSE:SLV) has appointed Mrs. Edyta Jaworska to the position of a Management Board Member, responsible for the development of its integrated drug discovery services.
Mrs. Jaworska joined Selvita in 2012, starting as a Business Development Manager responsible for the sales and development of Selvita offer in selected Western European countries. In 2014, she was promoted to the position of Business Development Director, taking over management of a sales team responsible for sales & development of Selvita services offer in Western Europe, Israel and Japan.
"As part of our continued corporate growth initiatives in the drug discovery services business segment we decided to strengthen our Management Board with Edyta, who has always excelled in her previous roles at Selvita and is responsible for the development of our integrated service activities" – comments Pawel Przewiezlikowski, Chief Executive Officer at Selvita.
"I have had the pleasure to be developing Selvita drug discovery and development services offer for the past few years. Thanks to an amazing work and great efforts of our scientific, operations and business development teams we have managed to introduce a broad set of new disease area competences, assays and infrastructure, develop the corporate skills and dynamically increase the share of integrated services in Selvita project portfolio. The appointment to the Selvita Management Board is not only a great honor for me, but also gives me the opportunity to develop new successful collaborations with leading global biotech and pharmaceutical industry partners and to broaden the existing relationships" comments Mrs. Jaworska.
Edyta Jaworska is a graduate of the University of Economics in Krakow, where she graduated with MSc in Economics and Post-graduate Studies Diploma in Finance Management. She also studied at the University of Southern Denmark in Odense. She also holds an MBA degree from Stockholm University and Krakow University of Economics joint program. Before she joined Selvita, she has gained several years of experience in managerial positions in various healthcare companies including OneMed group and International Nephrology Centers. Edyta is a classical music lover, plays piano and enjoys outdoor activities and travel with her family.
Selvita is one of the largest drug discovery companies in Europe, with two primary focus areas: to serve the drug discovery market as a customer centric provider of high quality, integrated drug discovery services, and as a drug discovery company engaged in the research and development of breakthrough therapies in oncology.
The company was established in 2007 and currently employs over 420 scientists, among which 30% are PhDs. Selvita is headquartered in Krakow, Poland, with a second research site in Poznan, Poland and foreign offices located in Cambridge, MA and San Francisco Bay Area, in the US, as well as in Cambridge, UK .
Selvita offers a wide range of drug discovery services including contract chemistry services, biology services, analytical chemistry and method validation, integrated drug discovery projects, as well as comparative studies of biosimilar medicinal products. Selvita’s laboratories are GLP and GMP-certified.
The company has alliances and service partnerships with more than one hundred large and medium-sized pharmaceutical and biotechnology companies from USA and Europe, including 8 of the top 10 largest pharmaceutical companies in the world.
+48 784 069 418